Examkin

Question

Difficulty: MediumMonitoring and Treatment Evaluation

A 32-year-old woman is admitted to the hospital with acute-onset right leg pain and swelling. Venous duplex ultrasonography reveals a deep vein thrombosis in the right femoral and popliteal veins. Her medical history is significant for systemic lupus erythematosus and antiphospholipid syndrome. She previously experienced a deep vein thrombosis three years ago and was treated with warfarin, but she discontinued all medications one year ago. Her vital signs are stable, and physical examination is notable only for right lower extremity pitting edema and erythema. She has no active bleeding.

Baseline laboratory studies obtained prior to treatment show:

Laboratory TestResultReference Range
Hemoglobin12.1 g/dL12.0-16.0 g/dL
Platelet count190,000/mm³150,000-400,000/mm³
Creatinine0.9 mg/dL0.6-1.1 mg/dL
Prothrombin time (PT)12.5 seconds11.0-15.0 seconds
Activated partial thromboplastin time (aPTT)82 seconds25-40 seconds

The physician orders a continuous intravenous infusion of unfractionated heparin for acute anticoagulation. Six hours after the initiation of the heparin infusion, a repeat aPTT is reported as >150 seconds. The patient continues to have no signs of bleeding.

Which of the following is the best next step in monitoring and evaluating this patient's anticoagulant therapy?

  1. Measure unfractionated heparin levels using an anti-factor Xa assayAnswer
  2. B
    Decrease the heparin infusion rate according to the standard nomogram and repeat the activated partial thromboplastin time in 6 hours
  3. C
    Interrupt the heparin infusion and immediately administer protamine sulfate
  4. D
    Order a 1:1 mixing study with normal plasma to confirm the presence of an inhibitor before adjusting the heparin dose
  5. E
    Switch the patient to subcutaneous low-molecular-weight heparin and monitor therapy with the activated partial thromboplastin time

Answer

Measure unfractionated heparin levels using an anti-factor Xa assay.
The correct answer is to measure unfractionated heparin levels using an anti-factor Xa assay. This patient has a known history of antiphospholipid syndrome, which frequently involves the presence of a circulating lupus anticoagulant. Lupus anticoagulants are autoantibodies that bind to phospholipids. Because the activated partial thromboplastin time (aPTT) assay relies on phospholipids to trigger coagulation in vitro, the presence of these antibodies causes a baseline prolongation of the aPTT. This is a purely in vitro phenomenon; in vivo, these patients are highly prothrombotic. When a patient with a prolonged baseline aPTT requires continuous unfractionated heparin therapy for an acute thrombosis, the aPTT becomes completely unreliable for monitoring the degree of anticoagulation. Attempting to use a standard aPTT nomogram in this setting often leads to dangerous underdosing of heparin and extension of the thrombus. Instead, clinicians must use the anti-factor Xa assay. This assay measures the specific ability of the patient's heparin-antithrombin complex to inhibit factor Xa; it does not utilize phospholipid reagents and is therefore not affected by the lupus anticoagulant.

Step-by-Step Solution

1
Analyze the patient's baseline laboratory values in the context of her medical history.
The baseline aPTT is significantly prolonged (82 seconds) prior to the administration of any anticoagulant, which is consistent with her history of systemic lupus erythematosus and antiphospholipid syndrome.
Antiphospholipid antibodies (specifically lupus anticoagulant) bind to the phospholipids used in the aPTT assay, causing an in vitro prolongation of the clotting time despite promoting a prothrombotic state in vivo.
2
Evaluate the standard monitoring protocol for the prescribed therapy.
Unfractionated heparin infusions are typically monitored using the aPTT, with dose adjustments made to achieve a target range (usually 1.5 to 2.5 times the normal baseline).
Heparin binds to antithrombin, enhancing its inhibition of thrombin and factor Xa, which is reflected in a prolonged aPTT.
3
Determine if the standard monitoring parameter is valid for this specific patient.
The aPTT is invalid for monitoring heparin in this patient.
Because the baseline aPTT is already artifactually prolonged by the lupus anticoagulant, the standard aPTT nomograms cannot accurately reflect the true degree of in vivo anticoagulation achieved by the heparin infusion.
4
Identify the most appropriate alternative monitoring test.
The anti-factor Xa assay should be ordered.
The anti-factor Xa assay directly measures the ability of heparin-bound antithrombin to inhibit factor Xa. It does not rely on phospholipid reagents and is therefore unaffected by the presence of a lupus anticoagulant.

Key Concept

In patients with antiphospholipid syndrome who have a prolonged baseline aPTT due to a lupus anticoagulant, the anti-factor Xa assay must be used instead of the aPTT to accurately monitor unfractionated heparin infusions.
Rate this question

Topics

Monitoring and Treatment Evaluation

More questions from this topic